Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivivi Health Sciences LLC

www.ivivihealthsciences.com

Latest From Novopharm Ltd.

Teva's Growth Trend

Teva's strategy of becoming a leading global supplier of generics by acquiring companies in the US and Europe is paying off--the company's revenues grew nearly 40% last year. Moreover, the company's first branded product, Copaxone for multiple sclerosis, is finally garnering strong growth after a slow start.
BioPharmaceutical Business Strategies

Say Good-bye to the Family Farm

Watson Pharmaceuticals Inc.'s purchase of Schein Pharmaceutical seems to confirm what generics industry experts have known for some time: the industry is consolidating at both the wholesaler and manufacturer levels. The purchase, for $674 million and the assumption of $240 million in debt, is the third time in the past year that a large generics maker has bought a rival. The deal puts Watson, now ranked number four in generics, in a race for first place with Teva Pharmaceutical Industries Inc., which has also been on a buying spree.
BioPharmaceutical Strategy

Whither Generics? Five Opinions

A few years ago, generics looked unstoppable; today, pricing's reached suicidal levels. As for generic substitution, patients would rather fight than switch.
BioPharmaceutical Business Strategies

Ranbaxy & Lilly: Flexibility in Building a Generics Business

Through Ranbaxy, the joint venture can provide its own raw materials and access highly efficient, low-cost manufacturing and development operations. Lilly contributes sales, marketing and regulatory know-how in the US and other Western markets.
BioPharmaceutical Middle East and Africa
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ivivi Technologies Inc.
  • Montvale Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ivivi Health Sciences LLC
  • Senior Management
  • Kathryn Clubb, CEO
  • Contact Info
  • Ivivi Health Sciences LLC
    Phone: (415) 814-2460
    330 Townsend St.
    Suite 100
    San Francisco, CA 90410
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register